BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
First Immunotherapy to Demonstrate Overall Survival Benefit Compared to Standard of Care in This Difficult-to-Treat Patient Population
Results Presented at EHA Presidential Symposium and Recognized as Top Abstract
Amgen - Investors - RSS Content
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.